Status:
WITHDRAWN
Endometrial Cancer Recurrence in Patients Taking Metformin
Lead Sponsor:
WellSpan Health
Conditions:
Recurrent Endometrial Carcinoma
Eligibility:
FEMALE
18-99 years
Brief Summary
Given the early literature available and its biological plausibility as an inhibitor of the mammalian target of rapamycin (mTOR) protein, it is hypothesized that women with endometrial cancer who take...
Detailed Description
This is a retrospective chart review study. Medical records are reviewed and data collected through the hospital's electronic medical record (EMR). Participants are women that had definitive treatment...
Eligibility Criteria
Inclusion
- Participants with endometrial cancer of all histologies treated in the WellSpan system from 2016-2020
Exclusion
- Participants who underwent palliative treatment for endometrial cancer
Key Trial Info
Start Date :
December 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 27 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05192850
Start Date
December 27 2021
End Date
February 27 2023
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
WellSpan
York, Pennsylvania, United States, 17403